Alle Studien
RekrutierungPhase I und Phase II (Integriert) - Erste Verabreichung an MenschenInterventionell

An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies

This study, called a Phase 1/2 trial, is looking at a new medicine called GEN3014 (also known as HexaBody®-CD38). It's for adults with certain blood cancers, specifically Multiple Myeloma, Diffuse Large B Cell Lymphoma, and Acute Myeloid Leukemia, that have either returned after treatment or haven't responded to other medicines. The main goals are to find out if GEN3014 is safe, what side effects it might cause, and if it helps to treat these cancers. Researchers will also compare it to an existing medicine, DARZALEX, in some cases. This is an early-stage study, meaning it's one of the first times this medicine is being given to people.

Auf einen Blick

Status
Rekrutierung
Phase
Phase I und Phase II (Integriert) - Erste Verabreichung an Menschen
Sponsor
Genmab A/S
Einschreibeziel
52
Starten
30 Sep 2024

Worum geht es in dieser Studie?

This study is a clinical trial, which is a type of medical research involving people. Its main purpose is to test a new medicine called GEN3014. This medicine is designed to treat certain blood cancers, specifically Multiple Myeloma, Diffuse Large B Cell Lymphoma, and Acute Myeloid Leukemia. These are cancers that affect blood cells and bone marrow. The study is particularly for people whose cancer has either come back after past treatments (relapsed) or hasn't responded to other medicines (refractory).

This trial is made up of two parts, called Phase 1 and Phase 2. Phase 1 trials are usually the first time a new medicine is given to people. The main focus at this stage is to check if the medicine is safe and to find the right dose. Phase 2 trials then look more closely at how well the medicine works, while still monitoring safety. The researchers will be carefully watching for any side effects and how the participants' bodies react to the medicine.

During the study, some participants will receive GEN3014, while others might receive DARZALEX, which is another medicine used for these conditions. By comparing the new medicine to an existing one, doctors can learn more about its potential benefits and risks. The goal is to see if GEN3014 could be a new and effective treatment option for these difficult-to-treat blood cancers.

Wichtige Erkenntnisse

  • Tests a new medicine (GEN3014) for specific blood cancers.
  • For adults whose cancer has returned or didn't respond to previous treatment.
  • Aims to check safety and how well the new medicine works.
  • Compares GEN3014 to an existing treatment (DARZALEX) in some cases.
  • Involves regular clinic visits and close health monitoring.
  • Die Teilnahme ist freiwillig, und Sie können jederzeit zurücktreten.

Wer könnte berechtigt sein?

To join this study, you must be at least 18 years old. Both men and women can take part. The study is specifically for people who have one of three types of blood cancer: Multiple Myeloma, Diffuse Large B Cell Lymphoma, or Acute Myeloid Leukemia.

It's important that your cancer has either come back after you've had treatment for it before, or that it hasn't responded to your previous treatments. The study is looking for people in these specific situations.

There might be other health requirements or previous treatment details that determine if you can join. A doctor involved in the study will review your full medical history to see if it’s a good fit for you.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Sind Sie 18 Jahre alt oder älter?
  2. Do you have Multiple Myeloma, Diffuse Large B Cell Lymphoma, or Acute Myeloid Leukemia?
  3. Has your cancer come back after a previous treatment?
  4. Or has your cancer not responded to previous treatments?
  5. Können Sie regelmäßige Kliniktermine wahrnehmen?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you decide to take part in this study, you will receive either the new medicine GEN3014 or a standard medicine named DARZALEX. You will come to the clinic regularly for check-ups. During these visits, doctors will closely monitor your health by taking blood samples, checking your vital signs (like blood pressure and heart rate), and performing heart checks using an electrocardiogram (ECG). They will also ask you about how you are feeling and any side effects you might be experiencing.

Some visits might involve longer stays for observation after you receive the medicine. The total length of your participation can vary depending on how you respond to the treatment and the phase of the study you are in, but it will involve ongoing follow-up visits to track your progress and long-term health. The doctors will explain the exact schedule and duration to you in detail.

Potenzielle Risiken und Vorteile

Participating in a clinical trial might offer potential benefits, such as receiving a new medicine that isn't widely available yet, which could help your condition if current treatments aren't working. You'll also receive close medical attention and monitoring. However, there are also potential risks. The new medicine, GEN3014, might cause side effects, some of which could be serious or unexpected, as it's still being tested. You will be told about all known risks before you make a decision. Remember, your participation is completely voluntary, and you have the right to withdraw from the study at any time, for any reason, without it affecting your future medical care.

Standorte (7)

Einige Standortangaben sind ungefähr. Wir arbeiten daran, dies zu verbessern — bitte überprüfen Sie die Angaben mit dem Versuchsteam, bevor Sie reisen.
  • —
    Unbestätigt
    Ungarn
  • —
    Unbestätigt
    Spanien
  • —
    Unbestätigt
    Tschechien
  • —
    Unbestätigt
    Schweden
  • —
    Unbestätigt
    Dänemark
  • —
    Unbestätigt
    Griechenland
  • —
    Unbestätigt
    Polen

Häufige Fragen

What kind of cancers is this study for?

This study is for adults with Multiple Myeloma, Diffuse Large B Cell Lymphoma, or Acute Myeloid Leukemia that have come back or not responded to previous treatments.

What is GEN3014?

GEN3014 is a new medicine being tested in this study to see if it can treat these specific blood cancers.

Werde ich das neue Medikament auf jeden Fall bekommen?

Some participants will receive GEN3014, while others might receive DARZALEX, an existing medicine, as part of the study design.

What does 'relapsed or refractory' mean?

It means your cancer has either returned after you've had treatment, or it hasn't responded to the treatments you've received.

Wie lange werde ich an der Studie teilnehmen?

The length of time you'd be in the study will depend on your response to treatment and the specific part of the study you're in. This will be explained in detail.

Wie Sie mehr erfahren können

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Interessiert daran, teilzunehmen?

Registrieren Sie Ihr Interesse

Teilen Sie Ihre Details und das Forschungsteam für "An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (Hexa… wird Sie kontaktieren, wenn Sie möglicherweise infrage kommen. Sprechen Sie immer mit Ihrem Hausarzt, bevor Sie zustimmen, teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.